GSK (GSK)
GSK Statistics
Share Statistics
GSK has 2.04B shares outstanding. The number of shares has increased by -0.25% in one year.
| Shares Outstanding | 2.04B |
| Shares Change (YoY) | -0.25% |
| Shares Change (QoQ) | -0.31% |
| Owned by Institutions (%) | 8.35% |
| Shares Floating | 2.03B |
| Failed to Deliver (FTD) Shares | 156.97K |
| FTD / Avg. Volume | 2.84% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is 21.41 and the forward PE ratio is 9.21. GSK's PEG ratio is -0.44.
| PE Ratio | 21.41 |
| Forward PE | 9.21 |
| PS Ratio | 1.76 |
| Forward PS | 1.6 |
| PB Ratio | 4.03 |
| P/FCF Ratio | 15.43 |
| PEG Ratio | -0.44 |
Enterprise Valuation
GSK has an Enterprise Value (EV) of 123.56B.
| EV / Sales | 3.94 |
| EV / EBITDA | 18.53 |
| EV / EBIT | 18.85 |
| EV / FCF | 34.59 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 1.24.
| Current Ratio | 0.78 |
| Quick Ratio | 0.52 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | 2.55 |
| Debt / FCF | 4.76 |
| Interest Coverage | 6.28 |
Financial Efficiency
Return on Equity is 18.84% and Return on Invested Capital is 8.51%.
| Return on Equity | 18.84% |
| Return on Assets | 4.33% |
| Return on Invested Capital | 8.51% |
| Revenue Per Employee | $457.18K |
| Profits Per Employee | $37.52K |
| Employee Count | 68,629 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.6 |
Taxes
| Income Tax | 526M |
| Effective Tax Rate | 15.13% |
Stock Price Statistics
The stock price has increased by -8.56% in the last 52 weeks. The beta is 0.3, so GSK's price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | -8.56% |
| 50-Day Moving Average | 37.51 |
| 200-Day Moving Average | 37.73 |
| Relative Strength Index (RSI) | 45.54 |
| Average Volume (20 Days) | 5.52M |
Income Statement
In the last 12 months, GSK had revenue of 31.38B and earned 2.58B in profits. Earnings per share was 0.63.
| Revenue | 31.38B |
| Gross Profit | 22.33B |
| Operating Income | 4.02B |
| Net Income | 2.58B |
| EBITDA | 6.67B |
| EBIT | 4.12B |
| Earnings Per Share (EPS) | 0.63 |
Balance Sheet
The company has 3.69B in cash and 16.99B in debt, giving a net cash position of -13.29B.
| Cash & Cash Equivalents | 3.69B |
| Total Debt | 16.99B |
| Net Cash | -13.29B |
| Retained Earnings | 7.8B |
| Total Assets | 59.46B |
| Working Capital | -4.7B |
Cash Flow
In the last 12 months, operating cash flow was 6.55B and capital expenditures -2.98B, giving a free cash flow of 3.57B.
| Operating Cash Flow | 6.55B |
| Capital Expenditures | -2.98B |
| Free Cash Flow | 3.57B |
| FCF Per Share | 0.88 |
Margins
Gross margin is 71.16%, with operating and profit margins of 12.82% and 8.21%.
| Gross Margin | 71.16% |
| Operating Margin | 12.82% |
| Pretax Margin | 11.08% |
| Profit Margin | 8.21% |
| EBITDA Margin | 21.25% |
| EBIT Margin | 12.82% |
| FCF Margin | 11.38% |
Dividends & Yields
GSK pays an annual dividend of $1.96, which amounts to a dividend yield of 4.23%.
| Dividend Per Share | $1.96 |
| Dividend Yield | 4.23% |
| Dividend Growth (YoY) | -1.33% |
| Payout Ratio | 120.1% |
| Earnings Yield | 4.67% |
| FCF Yield | 3.24% |
Analyst Forecast
The average price target for GSK is $47, which is 30.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $47 |
| Price Target Difference | 30.9% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jul 22, 2022. It was a forward split with a ratio of 613:500.
| Last Split Date | Jul 22, 2022 |
| Split Type | forward |
| Split Ratio | 613:500 |
Scores
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 6 |